ATHENS, Ga.--(BUSINESS WIRE)--ArunA Biomedical today announced it will present data at the 2018 International Society for Extracellular Vesicles (ISEV) Annual Meeting occurring May 2-6 in Barcelona, Spain. The data represent an extension of results from a study published in the May 2018 issue of Stroke in which the Company’s novel neural stem cell-derived extracellular vesicles (NSC EVs) preserved neuronal tissue structure and demonstrated functional recovery in pigs following ischemic stroke.
ArunA’s neural-derived exosomes, a form of EVs, are a new class of cell-free biologics and cell-mediated drug targeting systems being developed to treat central nervous system (CNS) and neurodegenerative disorders.
Details of the oral presentation are as follows:
Title: Human neural stem cell extracellular vesicles improve
recovery in a porcine model of ischemic stroke
Date: May 4,
2018
Time: 1:45 - 2:00pm CEST
Location: Palau de
Congressos de Barcelona-Fira Montjuic, Barcelona, Spain
Exosomes as Therapeutics
Since their discovery more than 30
years ago, extracellular vesicles — nanometer-sized cell-signaling
particles — have been increasingly found to play a role in intercellular
communication, capable of delivering functional proteins, mRNA
transcripts and miRNA to cells throughout the body. Exosomes have the
potential to target any cell in the body and as proved in ArunA’s
studies are capable of crossing the blood brain barrier non-invasively
to reach the site of injury. Exosomes have shown great promise as
potential therapeutics and as vehicles to carry drug payloads to the
site of injury or disease.
About ArunA Biomedical
At ArunA Biomedical, we are the
experts in the design and scaling of neural-derived exosomes, developing
a new class of cell-free biologics and cell-mediated drug delivery
systems to treat CNS and neurodegenerative disorders. www.arunabio.com
